Michael J. Perry


Michael Perry Photo

Washington, D.C.

P: +1.202.639.1318 F: +1.202.585.1024
  • Representing Novartis in the sale of its Sandoz division’s U.S. dermatology and generic oral solids portfolio to Aurobindo.
  • In re Humira Antitrust Litigation (N.D. Ill.). Representing Sandoz in defense of antitrust claims related to the settlement of patent infringement claims involving Sandoz’ biosimilar version of Humira.
  • Representing Indorama Ventures in its acquisition of Huntsman’s integrated oxides and derivatives businesses.
  • Representing Arch Coal in its proposed joint venture with Peabody Energy combining the companies’ Powder River Basin and Colorado assets.
  • Takeda v. Zydus (D.N.J.). Representing Zydus in sham litigation antitrust counterclaims.
  • Represented Indorama Ventures in its acquisition, through a joint venture, of M&G Chemicals’ integrated PTA-PET plant under construction in Corpus Christi, Texas.
  • Represented RealPage in its acquisition of Lease Rent Options and related assets from the Rainmaker Group.
  • Represented Rockwater Energy Solutions in its merger with Select Energy Solutions.
  • Sony v. Fujifilm (S.D.N.Y.). Represented Fujifilm in antitrust litigation and related actions relating to magnetic tape cartridges.
  • Haier America Trading v. Samsung Electronics (N.D.N.Y.). Represented Columbia University in antitrust and other claims involving digital television technology.
  • California v. Valero (N.D. Cal.) Represented Valero Energy in the California Attorney General’s challenge to the proposed acquisition of Plains All American Pipeline’s Bay Area terminals.
  • Advising leading pharmaceutical companies on Hatch-Waxman patent settlements.
  • Represented leading pharmaceutical company in worldwide research, development, and commercialization collaboration.
  • Represented trade associations in federal antitrust investigations.

While at the FTC, Mr. Perry's experience included:

  • Supervising merger and non-merger investigations in the healthcare, pharmaceutical, retail, grocery, energy, and technology industries.
  • FTC v. Cephalon (E.D. Pa.). Responsible for major components of the FTC's enforcement action alleging unlawful reverse-payment patent settlements, which resulted in the largest monetary settlement in agency history.
  • FTC v. Sysco (D.D.C.). Actively involved in the FTC's challenge to the proposed merger of Sysco and U.S. Foods.
  • FTC v. St. Luke's Health System (D. Idaho). Represented the FTC at trial and post-trial proceedings in challenge to a consummated healthcare merger.
  • FTC v. Actavis (N.D. Ga.). Following grant of certiorari, briefed and argued motion to unseal an exhibit attached to the FTC's complaint, which became part of the public Supreme Court record.
  • Actelion Pharmaceuticals v. Apotex (D.N.J.). Lead author of FTC amicus brief addressing whether a pharmaceutical company's refusal to sell product samples to generic competitors may violate the antitrust laws.